-
Generic drugs have no "money" way? The global giants spun off by MNC increased innovation
Time of Update: 2023-01-06
01 Hui Zhi began to harvest innovative pharmaceutical companiesHui Zhi began to harvest innovative pharmaceutical companiesOn November 7, generic drug giant Hui Zhi broke the news that the company agreed to buy Oyster Point at a cash price of $11 per share of all shares outstanding, for a total consideration of approximately $295 million.
-
Generic drugs have no "money" way? The global giants spun off by MNC increased innovation
Time of Update: 2023-01-06
01 Hui Zhi began to harvest innovative pharmaceutical companiesHui Zhi began to harvest innovative pharmaceutical companiesOn November 7, generic drug giant Hui Zhi broke the news that the company agreed to buy Oyster Point at a cash price of $11 per share of all shares outstanding, for a total consideration of approximately $295 million.
-
MNC's counterattack to the "bill": Lilly ends small molecule drug pipeline, AZ may never launch new cancer drugs in the United States again...
Time of Update: 2022-11-26
With the release of the 2022 Q3 performance report, in addition to summarizing the performance of the past three quarters, some pharmaceutical companies have also responded (counter) to a recently rel
-
AZ China's first rare disease drug on sale! Under the policy dividend, MNC has increased its layout of rare disease tracks
Time of Update: 2022-11-25
British pharmaceutical giant AstraZeneca announced that its rare disease drug eculizumab (Sulirui) opened its first order in Hangzhou on November 11, 2022, and was officially launched in China. The dr
-
Novartis antiepileptic drugs under supply pressure? MNC brand drug "Red Sea" is facing a breakthrough!
Time of Update: 2022-10-31
6 billion antiepileptic drugs market The share left for Qu Lai is getting smaller and smaller Developed by Novartis, oxcarbazepine was approved by the US FDA in 2000 and entered the Chinese market in 2004 under the trade name "Qulai".
-
Novartis antiepileptic drugs under supply pressure? MNC brand drug "Red Sea" is facing a breakthrough!
Time of Update: 2022-10-31
6 billion antiepileptic drugs market The share left for Qu Lai is getting smaller and smaller The share left for Qu Lai is getting smaller and smaller Developed by Novartis, oxcarbazepine was approved by the US FDA in 2000 and entered the Chinese market in 2004 under the trade name "Qulai".
-
to MNC or returning to China. The internationalization of innovative drugs is still "paying tuition"...
Time of Update: 2022-10-25
After wave of practice, the industry has begun to realize whether pharmaceutical companies have accumulated funds, provoked tens of millions of dollars in international multi-center clinical research expenses for foreign clinics, whether they have localized teams, understand the rules of the game in various countries, and whether they have a differentiated product foundation that can meet uncovered clinical needs and have promotion value.
-
German Merck increases M&A investment! Pfizer, AstraZeneca, Novo Nordisk and other MNCs
Time of Update: 2022-10-19
Merck said that the group plans to further increase global targeted investment and expand its leadership position in the field of bioscience and technology on the basis of its own research and development on the basis of its own research and development in the three core businesses of life science, health care and semiconductors from 2023.
-
GBI report | innovative open source, downsizing, non-core product sales... 12 MNC first-half results and strategic inventory
Time of Update: 2022-10-01
In the first half of 2022, the procurement of volume, the implementation of the medical insurance catalogue and the impact of the new crown epidemic have brought pressure to major multinational pharmaceutical companies that cannot be ignored; In particular, the sixth batch of national collection (insulin specialty), which has been implemented since May, has had an impact on the performance of Novo Nordisk, Eli Lilly and Sanofi.
-
The "Medical Insurance Negotiation" in the United States is about to land, stinging the nerves of the old MNC, will drug innovation be affected?
Time of Update: 2022-09-07
The 10 highest-priced prescription drugs in Medicare Part D are negotiated According to the forecast of Bank of America analysts, BMS' apixaban and O drugs, Johnson & Johnson's rivaroxaban, Merck's sitagliptin and K drugs, AbbVie's ibrutinib, Regeneron's aflibercept , Amgen's denosumab, etc.
-
Novartis officially announced the spin-off of Sandoz, and MNC and domestic pharmaceutical companies staged a "break-up"
Time of Update: 2022-09-07
Novartis announced that it plans to 100% divest its generic and biosimilar drug division Sandoz (Sandoz) into a newly listed independent operating company, which is expected to complete the spin-off process in the second half of next year .
-
August "earnings season": performance differentiation, structural adjustment... Local enterprises, MNC transformation busy!
Time of Update: 2022-09-06
AstraZeneca: New Vice President of China, from Novartis AstraZeneca: New Vice President of China, from Novartis On August 30, AstraZeneca announced the appointment of Liu Ming as Vice President of China, head of the Lung Cancer Treatment and Tumor Immunotherapy Related Areas Of the Oncology Division, base in Shanghai, joined the Chinese management team, and reported directly to Chen Kangwei, General Manager of AstraZeneca Oncology Division, effective August 30.
-
Tsingtao Brewery at the 2nd MNC Leaders Qingdao Summit
Time of Update: 2022-08-31
Responsible editor: Wang Jinchen Review: Zheng Ying On July 15, the 2nd Qingdao Summit of Multinational Company Leaders held the "Tsingtao Beer Night" themed salon in Qingdao, Shandong Province .
-
MNC's first half report card: Pfizer, Johnson & Johnson, Roche revenue TOP3!
Time of Update: 2022-08-20
6 billion, an increase of 19% year-on-year; the rare disease business grew rapidly, with total revenue reaching US$3.
6 billion, an increase of 19% year-on-year; the rare disease business grew rapidly, with total revenue reaching US$3.
-
MNC semi-annual report: Novartis, Johnson & Johnson, Abbott, Roche "lead the way"!
Time of Update: 2022-08-15
Profits of Novartis and Johnson & Johnson declined; Bojian’s net profit doubled in the second quarter, but the stock market fell; Abbott’s profit increased, but was still negatively affected by the recall and discontinuation of infant formula in February; Roche’s innovative drug performance far exceeded expectations, making up for the disadvantage of “old drugs” .